Results for valdecoxibs translation from Danish to English

valdecoxibs plasmaclearance (clp) er ca.6 l/time.
plasma clearance (clp) for valdecoxib is about 6 l/hr.

distribution valdecoxibs fordelingsvolumen efter i. v. administration er ca.55 liter.
10 distribution the volume of distribution of valdecoxib after its iv administration is approximately 55 litres.

valdecoxibs steady state plasmakoncentrationer nås inden for 4 dage ved dosering 2 gange dagligt.
steady state plasma concentrations of valdecoxib were reached within 4 days with twice daily dosing.

hos raske, ældre forsøgspersoner blev valdecoxibs tilsyneladende orale clearance reduceret med en ca.
in healthy elderly subjects, the apparent oral clearance of valdecoxib was reduced, resulting in an approximately 40% higher plasma exposure of valdecoxib

diurese eller alkalisering af urinen er muligvis ikke effektiv på grund af valdecoxibs høje proteinbinding.
diuresis or alkalisation of urine may not be useful due to high protein binding of valdecoxib.

valdecoxibs metabolisme kan øges, når det administreres sammen med enzyminducere, såsom rifampicin, phenytoin, carbamazepin eller dexamethason.
the metabolism of valdecoxib may increase when co-administered with enzyme inducers such as rifampicin, phenytoin, carbamazepine or dexamethasone.

andre lægemidlers virkning på parecoxibs (eller dets aktive substans valdecoxibs) farmakokinetik parecoxib hydrolyseres hurtigt til den aktive substans valdecoxib.
effects of other medicinal products on the pharmacokinetics of parecoxib (or its active metabolite valdecoxib) parecoxib is rapidly hydrolysed to the active metabolite valdecoxib.

samtidig administration af valdecoxib og glibenclamid (cyp3a4-substrat) påvirkede hverken glibenclamids farmakokinetik (eksponering) eller farmakodynamik (blodsukker og insulinniveauer).
co-administration of valdecoxib with glibenclamide (cyp3a4 substrate) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glibenclamide.